Results 61 to 70 of about 31,072 (141)
Zusammenfassung In diesem zweiten Teil der S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) stellen wir die zentralen Inhalte und Empfehlungen zur topischen und systemischen Therapie, zur Lebensqualität und zu Unterstützungsangeboten vor.
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla +33 more
wiley +1 more source
ABSTRACT A 31‐year‐old man with severe, corticosteroid‐resistant alopecia areata presented with substantial scalp hair loss (Severity of Alopecia Tool [SALT] score: 60%) despite a 1‐year regimen of topical corticosteroids, 5% minoxidil, and oral prednisolone. He was treated with allogeneic exosomes derived from adipose tissue mesenchymal stromal cells (
Masoumeh Kianpisheh +4 more
wiley +1 more source
Excellent response to tofacitinib treatment in a patient with alopecia universalis
Alopecia universalis (AU) is generally considered a variant of alopecia areata (AA), in which the treatment options seldom provide satisfactory results.
Erduran, F. +9 more
core +1 more source
S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 1: Diagnostik und Epidemiologie
Zusammenfassung In dem vom Innovationsausschuss beim gemeinsamen Bundesausschuss (G‐BA) geförderten Projekt wurde von 2023 bis 2025 die S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) entwickelt. Die interdisziplinäre Expertengruppe bestand aus Vertretern der Deutschen Dermatologischen Gesellschaft, insbesondere aus der AG ...
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
Evidence Based Treatment of Alopecia Areata
Background: Alopecia areata is a chronic autoimmune disease, involving non-scarring hair loss, which affects hair follicles and sometimes nails. Hair loss pattern presents as patchy alopecia, ophiasis, ophiasis inversa (sisapho), reticularis or diffuse ...
Eva Hariani, Nelva K. Jusuf
doaj +1 more source
S3 guideline diagnostics and therapy of alopecia areata – Part 1: Diagnostics and epidemiology
Summary In the project funded by the Innovation Committee at the G‐BA, the S3 guideline for the diagnosis and treatment of AA was developed between 2023 and 2025. The interdisciplinary expert panel consisted of representatives from the German Dermatological Society, in particular from the Pediatric Dermatology Working Group, the Professional ...
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
ABSTRACT Background Alopecia areata (AA) is an inflammatory, nonscarring hair loss disorder with significant variations in the clinical presentation and unpredictable nature of the disease. Although AA is common in clinical dermatology, knowledge gaps remain regarding the clinical characteristics and impact on patients' psychological well‐being and ...
Youyu Sheng +9 more
wiley +1 more source
Post-Treatment Residual Ophiasis in Severe Alopecia Areata, Alopecia Totalis/Universalis
Supplementary figure.1 detailing images of pattern IV ophiasis patients before and after treantments. Supplementary table. 1 detailing the rate of residual ophiasis following treatment in patients with alopecia universalis, alopecia totalis, and severe ...
Li, Fanshu
core +1 more source

